Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection For KIO-104 In The Treatment of Ocular Disease

Author: Benzinga Newsdesk | July 22, 2025 08:09am

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) today announced it has received a patent (US Patent No. 12,364,680) covering KIO-104 for the treatment of a wide range of ocular diseases. This includes, but is not limited to, the following conditions: ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. Additionally, the patent covers varying dosing schedules, necessary excipients, among other novel methods for optimizing treatment of ocular inflammatory diseases. This patent issuance is expected to further strengthen the protection of KIO-104 and extend market exclusivity into 2043.

Posted In: KPRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist